June 1, 2005 — Affymetrix Inc. (Nasdaq: AFFX) announced Tuesday that it has entered into an agreement to acquire ParAllele BioScience Inc., a privately held, South San Francisco-based company that provides assay technology for comprehensive genetic studies.
The acquisition builds on a two-year collaboration between the two companies. By acquiring ParAllele, Affymetrix says it expects to strengthen its assay R&D capabilities, accelerate its development and commercialization of new products, and drive sales by opening new market opportunities.
Affymetrix will pay approximately $120 million in stock to acquire ParAllele. The transaction is expected to close in the third quarter of 2005, pending regulatory approval.